Literature DB >> 17017912

Natural products from plants as drug candidates and lead compounds against leishmaniasis and trypanosomiasis.

Manar M Salem1, Karl A Werbovetz.   

Abstract

Millions of people in the developing world are affected by diseases caused by the kinetoplastid parasites: the leishmaniases, African trypanosomiasis, and Chagas disease. In many cases the drugs employed for treatment are toxic, marginally effective, given by injection, and/or compromised by the development of resistance. Since safe, effective, and affordable chemotherapeutic agents for leishmaniasis and trypanosomiasis are clearly needed, the identification of new antikinetoplastid drug candidates should be an urgent priority. Numerous plant-derived natural products from different structural classes have been investigated as antileishmanial and antitrypanosomal candidates, including various alkaloids, terpenoids, flavonoids, and quinonoids. This review outlines the antikinetoplastid activities of plant-derived natural products reported in the literature and also provides an overview of mechanistic studies that have been conducted with these compounds. Given the activities of these agents and their diverse range of effects on parasite biology, natural products are a potentially rich source of drug candidates and leads against leishmaniasis and trypanosomiasis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17017912     DOI: 10.2174/092986706778201611

Source DB:  PubMed          Journal:  Curr Med Chem        ISSN: 0929-8673            Impact factor:   4.530


  24 in total

1.  In vitro and in vivo efficacy of novel flavonoid dimers against cutaneous leishmaniasis.

Authors:  Iris L K Wong; Kin-Fai Chan; Yun-Fu Chen; Zhao-Rong Lun; Tak Hang Chan; Larry M C Chow
Journal:  Antimicrob Agents Chemother       Date:  2014-03-31       Impact factor: 5.191

2.  Northalrugosidine is a bisbenzyltetrahydroisoquinoline alkaloid from Thalictrum alpinum with in vivo antileishmanial activity.

Authors:  C Benjamin Naman; Gaurav Gupta; Sanjay Varikuti; Heebyung Chai; Raymond W Doskotch; Abhay R Satoskar; A Douglas Kinghorn
Journal:  J Nat Prod       Date:  2015-01-28       Impact factor: 4.050

3.  Investigational drugs for visceral leishmaniasis.

Authors:  Shyam Sundar; Jaya Chakravarty
Journal:  Expert Opin Investig Drugs       Date:  2014-11-20       Impact factor: 6.206

4.  Catalyst-controlled formal [4 + 3] cycloaddition applied to the total synthesis of (+)-barekoxide and (-)-barekol.

Authors:  Yajing Lian; Laura C Miller; Stephen Born; Richmond Sarpong; Huw M L Davies
Journal:  J Am Chem Soc       Date:  2010-09-08       Impact factor: 15.419

5.  Potential therapeutic use of herbal extracts in trypanosomiasis.

Authors:  Thaise L Teixeira; Samuel Cota Teixeira; Claudio Vieira da Silva; Maria A de Souza
Journal:  Pathog Glob Health       Date:  2013-12-19       Impact factor: 2.894

6.  Synthetic modification of manzamine A via Grubbs metathesis. Novel structures with enhanced antibacterial and antiprotozoal properties.

Authors:  Jeffrey D Winkler; Allyn T Londregan; Mark T Hamann
Journal:  Org Lett       Date:  2007-10-05       Impact factor: 6.005

7.  Activity of 8.O.4'-neolignans against Trypanosoma cruzi.

Authors:  Isabel Nocito; María Victoria Castelli; Susana A Zacchino; Esteban Serra
Journal:  Parasitol Res       Date:  2007-08-17       Impact factor: 2.289

8.  Antileishmanial constituents of the Panamanian endophytic fungus Edenia sp.

Authors:  Sergio Martínez-Luis; Gina Della-Togna; Phyllis D Coley; Thomas A Kursar; William H Gerwick; Luis Cubilla-Rios
Journal:  J Nat Prod       Date:  2008-12       Impact factor: 4.050

9.  Inhibitory activity of marine sponge-derived natural products against parasitic protozoa.

Authors:  Ilkay Orhan; Bilge Sener; Marcel Kaiser; Reto Brun; Deniz Tasdemir
Journal:  Mar Drugs       Date:  2010-01-15       Impact factor: 5.118

10.  Crystal structure of the Leishmania major phosphodiesterase LmjPDEB1 and insight into the design of the parasite-selective inhibitors.

Authors:  Huanchen Wang; Zier Yan; Jie Geng; Stefan Kunz; Thomas Seebeck; Hengming Ke
Journal:  Mol Microbiol       Date:  2007-10-17       Impact factor: 3.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.